IL276188A - Antibodies against CD47 which do not cause significant agglutination of red blood cells - Google Patents
Antibodies against CD47 which do not cause significant agglutination of red blood cellsInfo
- Publication number
- IL276188A IL276188A IL276188A IL27618820A IL276188A IL 276188 A IL276188 A IL 276188A IL 276188 A IL276188 A IL 276188A IL 27618820 A IL27618820 A IL 27618820A IL 276188 A IL276188 A IL 276188A
- Authority
- IL
- Israel
- Prior art keywords
- antibodies
- red blood
- blood cell
- cause significant
- cell agglutination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018074055 | 2018-01-24 | ||
| PCT/CN2019/072929 WO2019144895A1 (en) | 2018-01-24 | 2019-01-24 | Anti-cd47 antibodies that do not cause significant red blood cell agglutination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL276188A true IL276188A (en) | 2020-09-30 |
Family
ID=67395823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276188A IL276188A (en) | 2018-01-24 | 2020-07-21 | Antibodies against CD47 which do not cause significant agglutination of red blood cells |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210070855A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3743108A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021511064A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200116109A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111629754B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019212674A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3089512A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL276188A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202006877PA (cg-RX-API-DMAC7.html) |
| TW (1) | TW201932493A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019144895A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114007646B (zh) * | 2019-06-25 | 2024-05-10 | 南京金斯瑞生物科技有限公司 | 抗cd47/抗tigit双特异抗体及其制备方法和应用 |
| CN114072426B (zh) * | 2019-07-08 | 2024-01-26 | 南京金斯瑞生物科技有限公司 | 抗cd47/抗pd-1双特异抗体及其制备方法和应用 |
| CN114096564A (zh) * | 2019-07-16 | 2022-02-25 | 南京金斯瑞生物科技有限公司 | 抗cd47/抗ctla-4双特异抗体及其制备方法和应用 |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| EP4039711A4 (en) * | 2019-07-23 | 2023-11-15 | Nanjing GenScript Biotech Co., Ltd. | Anti-cd47/anti-lag-3 bispecific antibody, preparation method therefor and use thereof |
| TW202108631A (zh) * | 2019-08-21 | 2021-03-01 | 大陸商和鉑醫藥(上海)有限責任公司 | 一種抗cd47抗原結合蛋白及其應用 |
| JP7808546B2 (ja) | 2019-09-03 | 2026-01-29 | 中山康方生物医▲藥▼有限公司 | 抗cd47モノクローナル抗体及びその使用 |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Cd47、pd-l1に特異的な抗体、およびその使用 |
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CN112679611B (zh) * | 2021-01-18 | 2022-06-10 | 倍而达药业(苏州)有限公司 | 人源化cd47抗体或其抗原结合片段及应用 |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| TWI869582B (zh) * | 2020-04-10 | 2025-01-11 | 大陸商和記黃埔醫藥(上海)有限公司 | 抗cd47抗體及其用途 |
| WO2022003568A1 (en) | 2020-06-30 | 2022-01-06 | Dcprime B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| WO2022010806A1 (en) * | 2020-07-06 | 2022-01-13 | ALX Oncology Inc. | Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays |
| CN120040592A (zh) * | 2020-07-31 | 2025-05-27 | 百奥泰生物制药股份有限公司 | Cd47抗体及其应用 |
| CA3187837A1 (en) * | 2020-08-04 | 2022-02-10 | Exelixis, Inc. | Cd47 binding agents and uses thereof |
| KR20230079393A (ko) * | 2020-09-28 | 2023-06-07 | 상하이 헨리우스 바이오테크, 인크. | 항 cd47 항체 및 사용 방법 |
| KR102757518B1 (ko) * | 2020-12-07 | 2025-01-21 | (주)이노베이션바이오 | Cd47에 특이적인 항체 및 이의 용도 |
| WO2022140659A2 (en) * | 2020-12-23 | 2022-06-30 | D-10 Therapeutics, Inc. | Anti-cd47 antibodies and uses thereof |
| US20250277031A1 (en) * | 2021-01-08 | 2025-09-04 | Beijing Hanmi Pharmaceutical Co., Ltd. | Antibody specifically binding to cd47 and antigen-binding fragment thereof |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ, インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| KR102757524B1 (ko) * | 2021-06-30 | 2025-01-21 | (주)이노베이션바이오 | Cd47에 특이적인 인간화 항체 및 이를 포함하는 cd47 관련 질환의 예방 또는 치료용 약학적 조성물 |
| US20240336681A1 (en) * | 2021-07-30 | 2024-10-10 | Ludwig-Maximilians-Universität München | Anti-cd47 antibodies and use thereof |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| CA3248911A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| EP4511127A1 (en) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN117257935A (zh) * | 2022-06-21 | 2023-12-22 | 广东菲鹏制药股份有限公司 | 一种含抗cd47抗体或其抗原结合片段的制剂及其制备方法和应用 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| CN115932271A (zh) * | 2022-09-02 | 2023-04-07 | 东曜药业有限公司 | 一种cd47抗体的试剂组合物及其应用 |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN119968212A (zh) * | 2022-10-14 | 2025-05-09 | 南京传奇生物科技有限公司 | 靶向cd47的抗体及其用途 |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120584133A (zh) * | 2022-12-29 | 2025-09-02 | 上海复宏汉霖生物技术股份有限公司 | 抗cd47抗体及使用方法 |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| JP2026522894A (ja) | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ, インコーポレイテッド | Kras調節化合物 |
| CN121568935A (zh) | 2023-07-26 | 2026-02-24 | 吉利德科学公司 | Parp7抑制剂 |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| EP4774280A1 (en) | 2023-09-08 | 2026-07-15 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20260130893A1 (en) | 2024-10-21 | 2026-05-14 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026136515A1 (en) | 2024-12-19 | 2026-06-25 | Gilead Sciences, Inc. | Parp7 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6818749B1 (en) * | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| JP4637749B2 (ja) * | 2003-11-11 | 2011-02-23 | 中外製薬株式会社 | ヒト化抗cd47抗体 |
| ME03512B (me) * | 2012-02-06 | 2020-04-20 | Inhibrx Inc | Cd47 antitijela i postupci za njihovu upotrebu |
| US20140140989A1 (en) * | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| HK1245154A1 (zh) * | 2014-12-30 | 2018-08-24 | 细胞基因公司 | 抗cd47抗体及其用途 |
| CN106084052B (zh) * | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | 抗cd47单克隆抗体及其应用 |
| TW201819413A (zh) * | 2016-11-28 | 2018-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Cd47抗體、其抗原結合片段及其醫藥用途 |
-
2019
- 2019-01-24 CN CN201980009335.0A patent/CN111629754B/zh active Active
- 2019-01-24 SG SG11202006877PA patent/SG11202006877PA/en unknown
- 2019-01-24 KR KR1020207024051A patent/KR20200116109A/ko not_active Ceased
- 2019-01-24 US US16/964,828 patent/US20210070855A1/en not_active Abandoned
- 2019-01-24 EP EP19743231.3A patent/EP3743108A4/en not_active Withdrawn
- 2019-01-24 WO PCT/CN2019/072929 patent/WO2019144895A1/en not_active Ceased
- 2019-01-24 JP JP2020540609A patent/JP2021511064A/ja active Pending
- 2019-01-24 AU AU2019212674A patent/AU2019212674A1/en not_active Abandoned
- 2019-01-24 CA CA3089512A patent/CA3089512A1/en active Pending
- 2019-01-24 TW TW108102787A patent/TW201932493A/zh unknown
-
2020
- 2020-07-21 IL IL276188A patent/IL276188A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202006877PA (en) | 2020-08-28 |
| CA3089512A1 (en) | 2019-08-01 |
| EP3743108A4 (en) | 2022-01-26 |
| AU2019212674A1 (en) | 2020-09-03 |
| JP2021511064A (ja) | 2021-05-06 |
| US20210070855A1 (en) | 2021-03-11 |
| TW201932493A (zh) | 2019-08-16 |
| CN111629754A (zh) | 2020-09-04 |
| EP3743108A1 (en) | 2020-12-02 |
| WO2019144895A1 (en) | 2019-08-01 |
| KR20200116109A (ko) | 2020-10-08 |
| CN111629754B (zh) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202006877PA (en) | Anti-cd47 antibodies that do not cause significant red blood cell agglutination | |
| IL280780A (en) | Anti-TIGIT antibodies | |
| IL273886B (en) | B-cell maturation antigen-binding proteins | |
| IL280013A (en) | Anti-IL36R antibodies | |
| SI3331910T1 (sl) | Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA) | |
| IL279352A (en) | IL-11RA antibodies | |
| SG11202001368SA (en) | Antigen-binding proteins tatrgeting shared antigens | |
| IL287440A (en) | Antigen-specific cd19-targeted car-t cells | |
| IL278010A (en) | Antibodies to galectin 10 | |
| SG11201707705UA (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| ZA202105220B (en) | Cell penetrating antibodies | |
| IL277030A (en) | Antibodies | |
| EP3280464A4 (en) | Immune cell trapping devices and methods for making and using the same | |
| GB201819540D0 (en) | T cell modification | |
| SG11202106171WA (en) | Anti-btla antibodies | |
| IL278862A (en) | Monospecific and multispecific anti-TMEFF2 antibodies and uses thereof | |
| EP3574197A4 (en) | ASYMMETRICAL INPUT PARTICLE SEPARATOR SYSTEM | |
| SG11202102114UA (en) | Anti-klrg1 antibodies | |
| SG11202008513WA (en) | De-immunised anti-erbb3 antibodies | |
| HUE053453T2 (hu) | Immunesszé teljesvér-mintákhoz | |
| GB201806084D0 (en) | Antibodies | |
| HK40036595A (en) | Anti-cd47 antibodies that do not cause significant red blood cell agglutination | |
| GB201819952D0 (en) | Antibodies | |
| GB201817309D0 (en) | Antibodies | |
| GB201817313D0 (en) | Antibodies |